{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:27:52Z","timestamp":1766158072976},"reference-count":55,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.3892\/ol.2017.6578","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T09:58:42Z","timestamp":1500112722000},"page":"3327-3336","source":"Crossref","is-referenced-by-count":7,"title":["Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature"],"prefix":"10.3892","volume":"14","author":[{"given":"Clemens B.","family":"Tempfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Schultheis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Hilal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Askin","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther A.","family":"Rezniczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,7,15]]},"reference":[{"key":"key20180108114437_b1-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdw306","article-title":"Global trends and predictions in ovarian cancer mortality","volume":"27","author":"Malvezzi","year":"2016","journal-title":"Ann Oncol"},{"key":"key20180108114437_b2-ol-0-0-6578","first-page":"288","article-title":"Recurrent epithelial ovarian cancer: An update on treatment","volume":"27","author":"Foley","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"key20180108114437_b3-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.18632\/oncotarget.12926","article-title":"Bevacizumab combined with chemotherapy for ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"key20180108114437_b4-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20180108114437_b5-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180108114437_b6-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180108114437_b7-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20180108114437_b8-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20180108114437_b9-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20180108114437_b10-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3892\/ijmm.2016.2724","article-title":"Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review)","volume":"38","author":"Wang","year":"2016","journal-title":"Int J Mol Med"},{"key":"key20180108114437_b11-ol-0-0-6578","first-page":"5767","article-title":"Therapeutic potential of thalidomide and its analogues in the treatment of cancer","volume":"35","author":"Sherbet","year":"2015","journal-title":"Anticancer Res"},{"key":"key20180108114437_b12-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/10799900360520397","article-title":"IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis","volume":"23","author":"Bauer","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"key20180108114437_b13-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/bies.200900103","article-title":"Thalidomide-induced limb defects: Resolving a 50-year-old puzzle","volume":"31","author":"Vargesson","year":"2009","journal-title":"Bioessays"},{"key":"key20180108114437_b14-ol-0-0-6578","first-page":"358","article-title":"Thalidomide and congenital malformations","volume":"1","author":"McBride","year":"1961","journal-title":"Lancet"},{"key":"key20180108114437_b15-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1634\/theoncologist.1-3-180","article-title":"Anticancer drug development: The way forward","volume":"1","author":"Connors","year":"1996","journal-title":"Oncologist"},{"key":"key20180108114437_b16-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"e4239","DOI":"10.1097\/MD.0000000000004239","article-title":"Thalidomide for inflammatory bowel disease: Systematic review","volume":"95","author":"Bramuzzo","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key20180108114437_b17-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"28938","DOI":"10.18632\/oncotarget.4727","article-title":"Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivo","volume":"6","author":"Milanovic","year":"2015","journal-title":"Oncotarget"},{"key":"key20180108114437_b18-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12072-014-9557-1","article-title":"Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide","volume":"9","author":"Liang","year":"2015","journal-title":"Hepatol Int"},{"key":"key20180108114437_b19-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"11081","DOI":"10.1007\/s13277-016-4963-8","article-title":"Thalidomide treatment for patients with previously untreated multiple myeloma: A meta-analysis of randomized controlled trials","volume":"37","author":"Gao","year":"2016","journal-title":"Tumour Biol"},{"key":"key20180108114437_b20-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ceb.2015.10.004","article-title":"Lenalidomide: Deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond","volume":"37","author":"Guirguis","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"key20180108114437_b21-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14656560802627903","article-title":"Lenalidomide: A novel anticancer drug with multiple modalities","volume":"10","author":"Galustian","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"key20180108114437_b22-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/pbc.21333","article-title":"Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy","volume":"50","author":"Kanwar","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"key20180108114437_b23-ol-0-0-6578","first-page":"583","article-title":"Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: A report of 2 cases","volume":"54","author":"Phippen","year":"2009","journal-title":"J Reprod Med"},{"key":"key20180108114437_b24-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ygyno.2007.11.005","article-title":"Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer","volume":"111","author":"Buttin","year":"2008","journal-title":"Gynecol Oncol"},{"key":"key20180108114437_b25-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/tcm.1770050304","article-title":"Teratogen metabolism: Spontaneous decay products of thalidomide and thalidomide analogues are not bioactivated by liver microsomes","volume":"5","author":"Braun","year":"1985","journal-title":"Teratog Carcinog Mutagen"},{"key":"key20180108114437_b26-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/0006-291X(81)91214-6","article-title":"Thalidomide metabolite inhibits tumor cell attachment to concanavalin A coated surfaces","volume":"98","author":"Braun","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180108114437_b27-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/10799900360520397","article-title":"IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis","volume":"23","author":"Bauer","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"key20180108114437_b28-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1158\/0008-5472.CAN-04-3789","article-title":"Suppression of urokinase receptor expression by thalidomide is associated with inhibition of nuclear factor kappaB activation and subsequently suppressed ovarian cancer dissemination","volume":"65","author":"Kobayashi","year":"2005","journal-title":"Cancer Res"},{"key":"key20180108114437_b29-ol-0-0-6578","first-page":"186","article-title":"Study of thalidomide on the growth and angiogenesis of ovary cancer SKOV3 transplanted subcutaneously in nude mice","volume":"40","author":"Li","year":"2005","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"key20180108114437_b30-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/1471-2407-13-331","article-title":"Effects of hypoxia on human cancer cell line chemosensitivity","volume":"13","author":"Strese","year":"2013","journal-title":"BMC Cancer"},{"key":"key20180108114437_b31-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1684\/ecn.2013.0342","article-title":"Thalidomide distinctly affected TNF-8.5, IL-6 and MMP secretion by an ovarian cancer cell line (SKOV-3) and primary ovarian cancer cells","volume":"24","author":"Piura","year":"2013","journal-title":"Eur Cytokine Netw"},{"key":"key20180108114437_b32-ol-0-0-6578","first-page":"S17","article-title":"Thalidomide in solid tumors: The London experience","volume":"14","author":"Eisen","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"key20180108114437_b33-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdh300","article-title":"Thalidomide in cancer medicine","volume":"15","author":"Eleutherakis-Papaiakovou","year":"2004","journal-title":"Ann Oncol"},{"key":"key20180108114437_b34-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1358\/dot.2007.43.4.1062668","article-title":"Strategies for suppressing angiogenesis in gynecological cancers","volume":"43","author":"Ma","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"key20180108114437_b35-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14656560802627903","article-title":"Lenalidomide: A novel anticancer drug with multiple modalities","volume":"10","author":"Galustian","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"key20180108114437_b36-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/1049909111434044","article-title":"Palliative chemotherapy for malignant ascites secondary to ovarian cancer","volume":"29","author":"Malayev","year":"2012","journal-title":"Am J Hosp Palliat Care"},{"key":"key20180108114437_b37-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3109\/09513590.2013.801446","article-title":"Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: A novel treatment option","volume":"29","author":"Gadducci","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"key20180108114437_b38-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1097\/MPH.0000000000000387","article-title":"Long-term remission in a female with multiple relapsed juvenile granulosa cell tumor","volume":"37","author":"Benesch","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"key20180108114437_b39-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1006\/gyno.2001.6327","article-title":"Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor","volume":"82","author":"Jeyakumar","year":"2001","journal-title":"Gynecol Oncol"},{"key":"key20180108114437_b40-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","article-title":"Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer","volume":"82","author":"Eisen","year":"2000","journal-title":"Br J Cancer"},{"key":"key20180108114437_b41-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.2002.20.4.1147","article-title":"Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide","volume":"20","author":"Abramson","year":"2002","journal-title":"J Clin Oncol"},{"key":"key20180108114437_b42-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jpm.2006.0083","article-title":"Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer","volume":"10","author":"Gordinier","year":"2007","journal-title":"J Palliat Med"},{"key":"key20180108114437_b43-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2006.11.026","article-title":"Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma","volume":"105","author":"Zhang","year":"2007","journal-title":"Gynecol Oncol"},{"key":"key20180108114437_b44-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ygyno.2006.05.035","article-title":"Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma","volume":"103","author":"Chan","year":"2006","journal-title":"Gynecol Oncol"},{"key":"key20180108114437_b45-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.23164","article-title":"A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma","volume":"112","author":"Downs","year":"2008","journal-title":"Cancer"},{"key":"key20180108114437_b46-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ygyno.2010.08.002","article-title":"Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum\/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A gynecologic oncology group study","volume":"119","author":"Hurteau","year":"2010","journal-title":"Gynecol Oncol"},{"key":"key20180108114437_b47-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s10147-011-0243-1","article-title":"A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma","volume":"16","author":"Carter","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"key20180108114437_b48-ol-0-0-6578","first-page":"253","article-title":"A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis","volume":"32","author":"Muthuramalingam","year":"2011","journal-title":"Eur J Gynaecol Oncol"},{"key":"key20180108114437_b49-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10637-013-9966-3","article-title":"Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer","volume":"32","author":"Ganesan","year":"2014","journal-title":"Invest New Drugs"},{"key":"key20180108114437_b50-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/annonc\/mdu392","article-title":"A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma","volume":"25","author":"Selle","year":"2014","journal-title":"Ann Oncol"},{"key":"key20180108114437_b51-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1757-1626-1-143","article-title":"Thalidomide-related eosinophilic pneumonia: A case report and brief literature review","volume":"1","author":"Tilluckdharry","year":"2008","journal-title":"Cases J"},{"key":"key20180108114437_b52-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1345\/aph.1E608","article-title":"Dyspnea during thalidomide treatment for advanced ovarian cancer","volume":"39","author":"Gordinier","year":"2005","journal-title":"Ann Pharmacother"},{"key":"key20180108114437_b53-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/S0049-3848(16)30136-0","article-title":"PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non hodgkin lymphoma (NHL). A pooled data analysis of twelve clinical trials of fondazione italiana linfomi (FIL)","volume":"140","author":"Santi","year":"2016","journal-title":"Thromb Res"},{"key":"key20180108114437_b54-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00228-014-1662-5","article-title":"Off-label use of anticancer drugs in eastern Switzerland: A population-based prospective cohort study","volume":"70","author":"Joerger","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"key20180108114437_b55-ol-0-0-6578","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1185\/03007995.2012.688800","article-title":"Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms?","volume":"28","author":"Dasanu","year":"2012","journal-title":"Curr Med Res Opin"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T14:41:54Z","timestamp":1602513714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.6578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,15]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,7,15]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.3892\/ol.2017.6578"],"URL":"https:\/\/doi.org\/10.3892\/ol.2017.6578","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,15]]}}}